Who knew? Euphas2 and CovidThe severity of COVID-19 can also be affected by superimposed infections, which frequently occur in COVID-19 patients during long intensive care unit (ICU) stays [100,101,102]. Gram-negative bacteria are the most isolated bacteria in COVID-19 patients [103,104,105]. An international, prospective, observational web-based study (EUPHAS2 registry) reported that the use of polymyxin B-immobilized polystyrene column direct hemoperfusion (PMX-DHP) for two consecutive days in COVID-19 patients provides effective endotoxin adsorption and it is associated with hemodynamic stabilization [106]. Polymyxin B-immobilized polystyrene column is a medical device that uses the antibiotic polymyxin B to bind and neutralize lipid A, the active center of endotoxin in patients with COVID-19 and concomitant bacterial infections. As shown in previous studies [57,106], the use of PMX-DHP could be performed in selected patients with endotoxic shock unresponsive to standard treatment. Cytokine measurement pre-and post-PMX-DHP revealed decreased levels of IL-6 with a relatively high risk of circuit coagulation, probably related to septic shock. https://www.mdpi.com/2077-0383/11/21/6286
- EUPHAS-2 is a Spectral-sponsored observational study in Italy using EAA-guided PMX, which is now complete We have reviewed the topline results, which strongly support the preliminary data received from the Tigris trial. These data strengthen our confidence in our ability to achieve a successful trial outcome as well as potential FDA approval.
https://stockhouse.com/news/press-releases/2023/01/12/spectral-medical-provides-update-on-tigris-clinical-trial-and-other-business